logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Yuandong Biology (688513.SH): Perindopril Amlodipine Tablets (III) has obtained a drug registration certificate.

date
29/07/2025
Financial news app, Securities Times, reports that Yuandong Biotech (688513.SH) has announced that its fully owned subsidiary, Chengdu Suode Pharmaceutical Co., Ltd. (referred to as "Suode Pharmaceutical" below), recently received the "Drug Registration Certificate" issued by the National Medical Products Administration (NMPA) for the drug "Perindopril Amlodipine Tablets ()".
Latest
3 m ago
French eyewear manufacturer EssilorLuxottica achieved a 7.3% growth in revenue in the second quarter, surpassing analysts' expectations of a 5.93% growth.
3 m ago
J.P. Morgan upgraded Nike's rating to "Overweight" with a target price of $93, which boosted the stock price. Analysts believe that as major financial challenges are gradually resolved, combined with expected improvements by the end of 2025, Nike is expected to achieve a rebound in performance as long as it can effectively address regional market challenges.
4 m ago
J.P. Morgan raised Nike's rating, pointing out that potential risk factors for the company include a 20% decline in revenue in the Greater China region last quarter, mainly due to weak consumer demand and intensified competition. The performance of this region will be a key variable for sustained growth.
4 m ago
Figma (FIG.US) raised its IPO pricing range to $30-32 per share, targeting a valuation of $18.8 billion.
4 m ago
J.P. Morgan has upgraded Nike's rating, citing key positive factors including: - Relief from cost pressures: The new trade agreement reached with Vietnam in early July has eliminated tariff concerns. Nike originally expected $1 billion in costs impact from tariffs in fiscal year 2026, but now they can gradually absorb this impact through price increases and supply chain optimization. - Profit margin inflection point visible: Despite a 440 basis point year-on-year decline in gross margin to 40.3% in the fourth quarter of 2025, with continued pressure expected, the main financial impacts of the "Win Now" strategy have already been absorbed by the market, making the path to profit margin recovery clearer. The significant promotional activities carried out previously to clear inventory are now decreasing their suppressive effect on profit margins. - Effective product innovation: New products such as the Air Max Premium and Vomero 18 have received strong market responses, enhancing Nike's pricing power and market position against competitors like adidas and lululemon.
See all latestmore
logo
Contact US
qr
+852 - 60190728
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.